Forum on Drug Discovery, Development, and Translation: 2014 Annual Report (2015)

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Forum Sponsorship Forum Members (as of December 31, 2014) (as of December 31, 2014) Financial support for the Forum is derived from Membership in the Forum includes a private foundations, government agencies, diverse range of stakeholders from mul- industry sponsors, and nonprofit associations. tiple sectors, including government, the pharmaceutical and biotechnology indus- Private Foundations Burroughs Wellcome Fund tries, biomedical research funders and Doris Duke Charitable Foundation sponsors, academia, and patient groups. Other Nonprofit Organizations American Diabetes Association Jeffrey Drazen (Co-Chair) (until December 2014) American Society for Microbiology New England Journal of Medicine Association of American Medical Colleges Critical Path Institute Steven Galson (Co-Chair) FasterCures Amgen Inc. Friends of Cancer Research Russ Altman (Co-Chair) (as of January 2015) March of Dimes Foundation Stanford University Government Sponsors Margaret Anderson Food and Drug Administration FasterCures National Cancer Institute (NIH) Hugh Auchincloss National Center for Advancing Translational Sciences (NIH) National Institute of Allergy and National Institute of Allergy and Infectious Diseases (NIH) Infectious Diseases National Institute of Mental Health (NIH) National Institute of Neurological Disorders and Stroke (NIH) Christopher Austin National Center for Advancing Industry Sponsors Translational Sciences AbbVie Amgen Inc. Ann Bonham AstraZeneca Association of American Medical Eli Lilly & Co. Colleges GlaxoSmithKline Linda Brady Johnson & Johnson National Institute of Mental Health Merck & Co. Gail Cassell Pfizer, Inc. Harvard Medical School Department of Social and Sanofi Global Medicine (Visiting) Andrew Dahlem Eli Lilly & Co. January 20–21 May 12 Workshop: Financial Incentives Workshop: Characterizing and Communicating to Support Unmet Medical Needs Uncertainty in the Assessment of Benefits and for Nervous System Disorders Risks of Pharmaceutical Products (Day 2) 2015 June 10–11 October 7–8 Forum Meeting #28 Forum Meeting #29 

Forum Sponsorship and Membership James Doroshow Bernard Munos Ellen Sigal National Cancer Institute InnoThink Center for Research in Friends of Cancer Research Gary Filerman Biomedical Innovation Lana Skirboll Atlas Health Foundation Elizabeth (Betsy) Myers Sanofi Harry Greenberg Doris Duke Charitable Foundation Brian Strom Stanford University School of John Orloff Rutgers, the State University of New Medicine Baxter BioScience Jersey Kathy Hudson Rajesh Ranganathan Janet Tobias National Institutes of Health National Institute of Neurological Ikana Health Lynn Hudson Disorders and Stroke Joanne Waldstreicher Critical Path Institute Robert Ratner Johnson & Johnson S. Claiborne (Clay) Johnston American Diabetes Association Janet Woodcock Dell Medical School at the University Michael Rosenblatt FDA Center for Drug Evaluation and of Texas, Austin Merck & Co., Inc. Research Michael Katz Michael Severino March of Dimes Foundation AbbVie Liaison to the Board on Jack Keene James Shannon Health Sciences Policy Duke University Medical Center GlaxoSmithKline Robert Califf Rusty Kelley Duke University School of Medicine Burroughs Wellcome Fund Ronald Krall Membership University of Pittsburgh Freda Lewis-Hall Patient Pfizer, Inc. Advocacy Carol Mimura Government University of California, Berkeley Foundations and 10% Associations 22% Briggs Morrison 10% AstraZeneca Biotech/Other Industry 3% 17% Academia 25% Pharma 13% Miscellaneous Nonprofit October 20 March 26–27 Workshop: Priorities to Workshop: Enabling Rapid Advance the Field of Medical Countermeasure Regulatory Science Response to Emerging Threats March 17–18 June 23–24 October 21 Forum Meeting #30 Forum Meeting #31 Forum Meeting #32 

About the Forum on Drug Discovery, Development, and Translation About the Institute of Medicine The Institute of Medicine’s (IOM’s) Forum on Drug Discovery, The Institute of Medicine was established in Development, and Translation was created in 2005 by the IOM’s 1970 by the National Academy of Sciences to Board on Health Sciences Policy to provide a unique platform for secure the services of eminent members of dialogue and collaboration among thought leaders and stakehold- appropriate professions in the examination of ers in government, academia, industry, foundations, and patient policy matters pertaining to the health of the advocacy with an interest in improving the system of drug discovery, public. The Institute acts under the respon- development, and translation. The Forum brings together leaders sibility assigned to the National Academy of from private sector sponsors of biomedical and clinical research, Sciences by its congressional charter to serve federal agencies sponsoring and regulating biomedical and clinical as an advisor to the federal government research, the academic community, and patients, and in doing so and, upon its own initiative, to identify issues serves to educate the policy community about issues where science needing attention in the areas of medical and policy intersect. care, research, and education. The Forum convenes several times each year to identify and discuss Forum Staff key problems and strategies in the discovery, development, and Anne B. Claiborne, J.D., M.P.H. translation of drugs. To supplement the perspectives and expertise Senior Program Officer and Forum Director of its members, the Forum also holds public workshops to engage a Christopher J. DeFeo, Ph.D. wide range of experts, members of the public, and the policy com- Program Officer munity. The Forum also fosters collaborations among its members Rebecca A. English, M.P.H. and constituencies. For more information about the Forum on Drug Program Officer Discovery, Development, and Translation, please visit our website at Emily R. Busta, M.S. www.iom.edu/drug. Associate Program Officer Kathryn M. Howell Senior Program Assistant Elizabeth F. C. Tyson (until September 2014) Associate Program Officer Barret Zimmermann (until July 2014) Senior Program Assistant Board on Health Sciences Policy Andrew M. Pope, Ph.D. Director The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine embraces the health of people everywhere.